Nurix Therapeutics (NASDAQ:NRIX) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Nurix Therapeutics (NASDAQ:NRIX) posted its quarterly earnings data on Tuesday. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08), Zacks reports. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%.

Nurix Therapeutics Stock Down 1.3 %

Shares of NRIX stock traded down $0.25 during trading hours on Tuesday, hitting $19.56. 576,903 shares of the company’s stock were exchanged, compared to its average volume of 665,015. The firm has a market cap of $1.39 billion, a P/E ratio of -6.72 and a beta of 2.14. The firm has a 50 day moving average of $20.26 and a two-hundred day moving average of $22.45. Nurix Therapeutics has a fifty-two week low of $7.65 and a fifty-two week high of $29.56.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,437 shares of Nurix Therapeutics stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total transaction of $83,519.10. Following the sale, the insider now owns 50,670 shares of the company’s stock, valued at $1,231,281. The trade was a 6.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Houte Hans Van sold 2,368 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total transaction of $57,542.40. Following the transaction, the chief financial officer now owns 37,270 shares in the company, valued at $905,661. The trade was a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,351 shares of company stock valued at $227,158 over the last ninety days. Corporate insiders own 7.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on NRIX shares. HC Wainwright raised their price target on Nurix Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. UBS Group assumed coverage on shares of Nurix Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $35.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 price target on shares of Nurix Therapeutics in a report on Tuesday, December 10th. BTIG Research started coverage on shares of Nurix Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $35.00 price objective on the stock. Finally, Stephens restated an “overweight” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $30.35.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.